Voyager Therapeutics investor presentation filing

Voyager Therapeutics, Inc. furnished an investor presentation in connection with its appearance at Citi’s 2025 Biopharma Back to School Conference.

Accepted by SEC EDGAR 09/02/2025 - 07:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Voyager Therapeutics, Inc. furnished an investor presentation in connection with its appearance at Citi’s 2025 Biopharma Back to School Conference. The company plans to present the materials in Exhibit 99.1 on September 2, 2025 at 4:00 p.m. ET.

The presentation is being provided under Regulation FD and, along with Item 7.01, is treated as “furnished” rather than “filed,” which limits certain securities law liabilities and incorporation by reference. Voyager states it is not admitting the materiality of the information and notes that these materials should be read together with its other SEC filings and public disclosures, and it does not undertake an obligation to update them.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Voyager Therapeutics (VYGR) disclose in this Form 8-K?

Voyager Therapeutics furnished an investor presentation, attached as Exhibit 99.1, that it plans to use at Citi’s 2025 Biopharma Back to School Conference.

When and where is Voyager Therapeutics presenting this information?

Voyager Therapeutics plans to present the Exhibit 99.1 materials at Citi’s 2025 Biopharma Back to School Conference on September 2, 2025 at 4:00 p.m. ET.

Is the Voyager Therapeutics presentation considered filed with the SEC?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is being “furnished” and not “filed” under the Exchange Act, limiting certain Section 18 liabilities.

Does Voyager Therapeutics consider the Exhibit 99.1 information material?

Voyager specifically notes it is not making an admission as to the materiality of any information provided in Item 7.01 or Exhibit 99.1.

Will Voyager Therapeutics update the information in this presentation?

The company states it undertakes no duty or obligation to update or revise the information, though it may do so through future SEC filings or other public disclosures.

Who signed the Voyager Therapeutics Form 8-K related to the presentation?

The Form 8-K was signed on behalf of Voyager Therapeutics by Nathan Jorgensen, Ph.D., the company’s Chief Financial Officer and principal financial and accounting officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001640266 0001640266 2025-09-02 2025-09-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 2, 2025

Voyager Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37625		46-3003182
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

75 Hayden Avenue Lexington, Massachusetts		02421
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (857) 259-5340

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	VYGR	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

Voyager Therapeutics, Inc. (the “Company”), plans to present the information in the presentation attached hereto as Exhibit 99.1 (the “Presentation”) at Citi’s 2025 Biopharma Back to School Conference on September 2, 2025 at 4:00 p.m. ET.

A copy of the Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including Item 7.01 and Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

By providing the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, the Company is not making an admission as to the materiality of any information herein. The information contained in this Current Report on Form 8-K is intended to be considered in the context of more complete information included in the Company’s filings with the SEC and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Voyager Therapeutics, Inc. Presentation September 2025
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 2, 2025	VOYAGER THERAPEUTICS, INC.
	By:	/s/ Nathan Jorgensen, Ph.D.
		Nathan Jorgensen, Ph.D.
		Chief Financial Officer
		(Principal Financial and Accounting Officer)